Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MD-711 (inhaled treprostinil) Phase 2/3 Study in Pulmonary Arterial Hypertension
jRCT2080224582Phase 3Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Mar 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by Mochida Pharmaceutical Co., Ltd. Started Mar 2019; status: completed.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2080224582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224582.